No Data
Japan Tissue Engineering, Sysmex Ink Regenerative Medicine Manufacturing Deal
Japan Tissue Engineering: Half Year Report - Term 27 (2024/04/01 - 2025/03/31)
Stocks that moved the previous day part 2: Fujikogane E&C, Moneypartners Group, RSC, etc.
Concerns about limited financial surprises and future reduction in system development projects.
Weakness, weighed down by factors such as falling US stocks [emerging markets individual stock strategy]
[Emerging Markets Individual Stock Strategy] Today, a subdued development is expected in the emerging markets. In the U.S. stock market on October 31st, the Dow Jones Industrial Average fell by $378.08 (-0.90%) to 41,763.46, marking a third consecutive decline. Adjusted selling pressure due to the Core PCE Price Index exceeding expectations and pending employment statistics at the end of the month weighed on the market. Additionally, the decline of Microsoft (MSFT) and Meta Platforms (META) dragged down stock prices. Furthermore, Iran is involved in a large-scale conflict with Israel.
Japan Tissue Engineering 1H Parent Loss Y225.00M Vs Loss Y11.00M
Japan Tissue Engineering: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending March 31, 2025